can retatrutide cause pancreatitis side effects: what the trials show and how to manage them Friendly reminder: retatrutide is a

Kaur K, Margolin E

Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH

Author contributions All authors contributed to conception and design, analysis and interpretation of the evidence, drafting of the manuscript, finalization of the manuscript, and the decision to submit to publication

However, whether GIPR or GCGR agonist exerts an independent effect remain unclear